BML, Inc. (4694.T)

Executive Summary

BML, Inc. is a leading Japanese clinical laboratory testing provider, generating steady revenue from medical testing, health check-ups, and contract research services. The company holds a dominant position in the domestic diagnostics market, supported by an extensive facility network. While BML has explored biotech drug development, its sole pipeline candidate (macitentan for CTEPH) was terminated in Phase 3, leaving near-term growth dependent on its core testing business. With a market capitalization of approximately ¥143 billion (≈$1 billion), BML offers stable cash flows but limited catalysts for significant upside. The stock is listed on the Tokyo Stock Exchange under ticker 4694.T.

Upcoming Catalysts (preview)

• Q3 2026Q3 2026 earnings release90% success